Paradigm was quick to release two back to back updates within one week
All good .. except their TP remained fixed.
I wonder if they'll soon revert back to their previous targets ( closer to $4)
now that most of the past reasons for downgrades to the TP have been removed. These include:
- poor enrolment pace, and time distance to final FDA decision
- uncertainty about Baxter's future commitment to supporting the PMX Trial
-uncertainty about future cash in flows ( like Baxter, warrant financing, etc.)
- uncertainty of approval ( they are now using 100%)
- time value of money. Future cash streams are being brought forward through the improving pace of enrolment and more sites
So shouldn't the TP pendulum start to move in the opposite direction?
MM